QN-030a / Qihan Biotech - LARVOL DELTA

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | N=18 ➔ 1 | Recruiting ➔ Terminated; It did not reach the expected results of clinical trial

Enrollment change • Minimal residual disease • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Natural Killer(NK) Cell Therapy in r/r AML (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Zhejiang University

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital

Minimal residual disease • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology